Sat, Jan 31, 2015, 12:09 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • stupid_hobo73 stupid_hobo73 Nov 10, 2010 11:26 AM Flag


    ....maintains "BUY" rating and raises price target back up to $22:

    11/09/10 09:54 am ET ... S&P REITERATES BUY
    (GHDX 17.64****): Q3 EPS of $0.12, vs. loss of
    $0.02, is well ahead of our $0.01 loss estimate,
    as product sales rose 18% and tests delivered
    increased 17%. Average selling price was
    strong, as reimbursement improved despite limited
    reimbursement for its colon test.We expect
    reimbursement worldwide to increase
    over the next several quarters.We are also encouraged
    by its geographic expansion with international
    sales now accounting for 10% of
    tests. But we expect costs to increase significantly
    as GHDX continues its expansion.We
    are raising our target price to $22 from $18.

32.28-0.10(-0.31%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Visa Inc.
NYSEFri, Jan 30, 2015 4:00 PM EST Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST